Objective: We investigated the differential effects of the antipsychotic drugs olanzapine and haloperidol on MK-801-induced memory impairment and neurogenesis in mice. Methods: MK-801 (0.1 mg/kg) was administered 20 minutes prior to behavioral testing over 9 days. Beginning on the sixth day of MK-801 treatment, either olanzapine (0.05 mg/kg) or haloperidol (0.05 mg/kg) was administered 40 minutes prior to MK-801 for the final 4 days. Spatial memory performance was measured using a Morris water maze (MWM) test for 9 days (four trials/day). Immunohistochemistry with bromodeoxyuridine (BrdU) was used to identify newborn cells labeled in tissue sections from the dentate gyrus of the hippocampus. Results: MK-801 administration over 9 days significantly impaired memory performance in the MWM test compared to untreated controls (p＜0.05) and these deficits were blocked by treatment with olanzapine (p＜0.05) but not haloperidol. The administration of MK-801 also resulted in a decrease in the number of BrdU-labeled cells in the dentate gyrus (28.6%; p＜0.01), which was prevented by treatment with olanzapine (p＜0.05) but not haloperidol. Conclusion: These results suggest that olanzapine has a protective effect against cognitive impairments induced by MK-801 in mice via the stimulating effects of neurogenesis.
INTRODUCTION
Schizophrenia is a severe chronic illness with a debilitating course in which patients suffer from multiple episodes. In the aftermath of schizophrenic episodes, the impairment of social and occupational function may continue. 1) Schizophrenia consists of several symptom domains that shows different response to treatment. 2) Among symptom domains of schizophrenia, cognitive symptoms may be persisting after successful treatment of positive symptoms and may affect social and occupation functions of the patients of schizophrenia. 2) First generation antipsychotic (FGA) drugs, such as haloperidol and chlorpromazine, have been used to treat schizophrenia and show efficacy for relieving the psychotic symptoms of schizophrenia.
3) However, FGAs failed to show improvement on cognitive dysfunction. 4) Some second generation antipsychotic (SGA) drugs, such as olanzapine and quetiapine, are not only efficacious for the treatment of delusions and hallucinations but also have positive effects on mood and cognitive symptoms. 4, 5) Moreover, some SGAs has been known to have possible neuroprotective effects and these effects might be related with cognitive functions. 6) As schizophrenia progresses the volume of the cerebral cortex decreases. 7) For example, Thompson et al. 7) found a decreased cerebral cortical volume in early-onset first-episode schizophrenia patients after 2 years of olanzapine or haloperidol treatment. A decreased brain volume was associated with haloperidol but not olanzapine. 6) Based on such clinical findings, it appears that olanzapine may have neuroprotective effects relative to cognitive function. In addition, a growing body of experimental evidence from in vivo and in vitro studies has demon- Fig. 1 . Schematic diagram of experiment schedule. MK-801 (0.1 mg/kg) was administered 20 minutes prior to behavioral testing for a total of 9 days. Following 6 days of treatment with MK-801, either olanzapine (0.05 mg/kg) or haloperidol (0.05 mg/kg) was administered 40 minutes prior to administration of MK-801 for a total of 4 days. Spatial memory performance was measured in a Morris water maze test over 9 days (4 trials/day). strated that some SGAs have neuroprotective effects whereas FGAs, such as haloperidol, do not. In fact, FGAs may even cause oxidative stress, which can result in apoptotic cell death. [8] [9] [10] [11] [12] [13] [14] [15] As mentioned above, based on research that has investigated long-term treatments for schizophrenia and on opinions from brain mapping, it can be presumed that SGAs have neuroprotective effects.
MK-801 is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and repeated injection of MK-801 has been known to induce schizophrenia-like behavioral alternations and metabolic changed in animal brains. [16] [17] [18] [19] [20] Repeated MK-801 injections also impairs learning and memory functions or rat [21] [22] [23] and reduces neurogenesis and brain-derived neurotrophic factor (BDNF) in the rat hippocampus. 24, 25) In the present study, we used repeated MK-801 injections for making impaired cognitive model and evaluated whether the differential effects of the antipsychotic drugs olanzapine and haloperidol. Morris water maze (MWM) test was used for the evaluation of cognitive functions. In addition, we evaluate the effects of these drugs on hippocampal neurogenesis with immunohistochemistry.
METHODS

Animals
All animal manipulations were performed in accordance with the animal care guidelines of the US National Institutes of Health (NIH publication no. 23-85, revised 1996) 
Drug Treatment
This study utilized MK-801 and haloperidol (Sigma, St. Louis, MO, USA) and olanzapine (Eli Lilly Research Laboratories, Indianapolis, IN, USA). Olanzapine and haloperidol were dissolved in 0.3 M HCl in saline after which the pH was adjusted to 5.5-6.0 with sodium hydroxide.
26) MK-801 was dissolved in saline. The drugs dose was selected based on a Kant et al. 27) and previous study from our lab (data not shown). In the water maze experiment, MK-801 (0.1 mg/kg) was administered 20 minutes prior to behavioral testing over 9 days. 28) Beginning on the sixth day of MK-801 treatment, either olanzapine (0.05 mg/kg) or haloperidol (0.05 mg/kg) was given 60 minutes prior to behavioral testing, which was 40 minutes prior to MK-801 treatment, for 4 days (Fig. 1 ).
Morris Water Maze Test
The MWM test is a behavioral task that is a commonly used model for learning and memory research. A circular swimming pool measuring 150 cm in diameter and 50 cm in height was filled to a depth of 35 cm with water that was kept at 26±2 o C and clouded with a colored white dye (Tempera; Fine Art Supplies, Auckland, New Zealand) to make the platform invisible. Four equally spaced points around the edge of the pool were designated east (E), south (S), west (W), and north (N). An escape platform (12 cm in diameter) was set 1 cm below the surface of the water and placed in a constant position in the middle of the SE quadrant. The swim paths of the mice were automatically recorded using the HVS image-tracking system (HVS Image, Hampton, UK). 29 ) Each subject performed the task four times daily in intervals of 1 minute and trials began by placing a mouse by hand into the water facing the wall of the circular pool at the E, S, W, or N points around the edge of the pool. Mice were allowed to swim to the hidden platform and the escape latency was recorded. After reaching the platform, the mice were allowed to stay on the platform for 20 seconds and then gently moved to a drying cage where they stayed for 10 minutes before being returned to the home cage. If the mouse failed to find the platform within 1 minute, it was gently placed onto the platform where it was allowed to stay for 1 minute.
Bromodeoxyuridine (BrdU) Labeling
BrdU was prepared in saline at a dilution of 20 mg/ml BrdU. Solutions were dissolved by sonication and prepared on the same day they were used. To examine cell proliferation, BrdU was injected (200 mg/kg, i.p.) on the last day of MWM testing, 1 day before death. At 24 hours after injection, the subjects were deeply anesthetized and sacrificed with pentobarbital (50 mg/kg, i.p.) and then transcardially perfused with ice-cold phosphate-buffered saline (PBS, pH 7.4) followed by ice-cold 4% paraformaldehyde (Sigma) in PBS. Following perfusion, all brains were post-fixed in paraformaldehyde until use. Serial sections of 50 m were cut through the entire hippocampus 30) on a vibratome (Series 1000 Sectioning System; Technical Products International, O'Fallon, MO, USA) and stored in a 24-well plate with 4% formalin.
Immunohistochemistry
Free-floating sections were used to determine BrdU labeling. DNA was denatured by incubating the samples for 2 hours in 50% formamide/2X SSC at 65 o C followed by several 2X SSC rinses. Then the sections were incubated for 30 minutes in 3 M HCl at 37 o C and washed for 10 minutes in 0.1 M boric acid (pH 8.5) after being incubated in 0.3% TritonX-100 for 15 minutes. After the sections were washed with PBS and incubated for 30 minutes, proteinase K (1 g/ml; Amresco, Solon, OH, USA) was added at 37 o C. After rinsing with PBS, sections were incubated for 10 minutes in 3% H 2 O 2 to eliminate endogenous peroxidases. Then they were placed in a blocking serum (Novostain Super ABC kit; Novocastra, Newcastle, UK) in PBS for 1 hour and incubated overnight with anti-mouse BrdU (1:200; Dako, Glostrup, Denmark) at 4 o C.
The following day, the sections were incubated for 90 minutes with a secondary antibody (biotinylated horse anti-mouse; Vector Laboratories, Burlingame, CA, USA) followed by 1 hour in an avidin-biotin enzyme complex reagent. After washing in PBS, the reaction product was detected using diaminobenzidine (peroxidase substrate kit, SK-4100 DAB; Vector Laboratories). Sections were mounted onto gelatin-coated slides, dehydrated with a series of alcohol rinses (70%, 90%, and 100%), and incubated for 5 minutes in xylene after being coverslipped with Permount (SP15-500, Fisher Scientific, Waltham, MA, USA).
Statistical Analysis
For BrdU-labeled cells, counted sections spaced at least 160 m apart were subjected to a blind densitometric analysis via a digital image analysis system (Image-Pro Plus version 3.0; Media Cybernetics, Silver Spring, MD, USA). Sections were divided between the anterior, middle, and posterior thirds of the hippocampus (Bregma: −2.3 to −4.0 mm) and analyzed for BrdU immunostaining in an area encompassing the entire granule cell layer extending approximately two cell layer widths deep into the hilus (subgranular proliferative zone). Lighter-immunostained cells and small BrdU-labeled nuclei at the hilar border were excluded from the analysis. 31) The data are presented as mean±standard error of mean for three independent experiments, for each of which a oneway analysis of variance (ANOVA) was performed. Post hoc comparisons using Scheffe's and Duncan's test were performed and values were deemed significant at p＜0.05.
RESULTS
Effects of Olanzapine and Haloperidol in MK-801-injected Mice in the MWM Test
Escape latency
The escape latency (time to reach the platform) in the MWM test for the four groups is presented in Table 1 . Compared to the control group, there was an increased escape latency observed in MK-801-treated mice beginning on day 6 and continuing through day 9 (p＜0.05, Fig. 2A ). The escape latency on days 7 and 8 were decreased in olanzapine-treated mice (0.05 mg/kg) compared to MK-801-treated mice and this difference was significant on day 8 (p＜0.05, Fig. 2A) . Haloperidol (0.05 mg/kg) treatment did not affect the escape latency of MK-801-treated mice ( Fig. 2A) . 
Swimming distance
Compared to the control group, an increase in swimming distance was observed in MK-801-treated mice beginning on day 4 and continuing through day 9 and this difference was significant on days 6 and 7 (p＜0.05, Fig.  2B ). There were no differences of swimming distance between MK-801 treated-group and MK-801 plus olanzapine treated-group (Fig. 2B) . However, compared with in MK-801-treated group, haloperidol treated group resulted in a significant decrease in swimming distance was observed in haloperidol-treated group in day 6 and 7 (p＜0.05, Fig. 2B ).
Swimming speed
Haloperidol decreased swimming speed but this did not reach statistical significance (Fig. 2C) .
Effects of Olanzapine and Haloperidol on Hippocampal Neurogenesis Following MK-801 Administration
Hippocampal neurogenesis
Images of BrdU-labeled cells for all four groups are shown in Fig. 3A . The total proportions of BrdU-labeled cells from the control, MK-801, olanzapine＋MK-801, and 
DISCUSSION
The administration of antipsychotic drugs in conjunction with MK-801 over 4 days resulted in changes in memory function and neurogenesis according to the class of antipsychotic drug. Treatment with MK-801 impaired memory function in C57BL/6J mice but this deficit was restored by olanzapine, which also facilitated neurogenesis.
Olanzapine, but not haloperidol, reversed memory impairments in MK-801-treated mice during performance in the MWM test. A previous study 32) reported relatively long-term differential effects of SGAs and haloperidol on cognitive function in Wistar rats, where relative to olanzapine, haloperidol significantly impaired learning performance and decreased choline acetyltransferase (ChAT) in the cortex and hippocampus; in contrast, olanzapine treatment increased ChAT activity. Haloperidol impairs learning performance compared to risperidone and clozapine, which also reduce ChAT. 33) Moreover, haloperidol reduces levels of nerve growth factor in the rat brain and impairs performance in the MWM test. 34) These findings suggest that different types of antipsychotic drugs may have different effects on memory function and neurogenesis in the brain. In this study, the acute effects of antipsychotic drugs on memory function and neurogenesis were investigated. Pretreatment with MK-801 induced impairments in spatial learning performance in the MWM test. Five days of MK-801 treatment induced cognitive impairments and 9 days of MK-801 treatment reduced neurogenesis in the rat hippocampus. Mandillo et al. 35) reported that 5 days of repeated MK-801 administration selectively and differentially impairs the ability of mice to discriminate a spatial change. Zemanova et al. 36) observed that visuospatial working memory is impaired in an animal model of schizophrenia induced by acute treatment with MK-801. MK-801 is known to induce neurotoxicity. For example, Willis and Ray 37) found that MK-801 results in cortical neurotoxicity in the rat brain. Likewise, the repeated administration of MK-801 results in a decreased number of BrdU-labeled cells in the dentate gyrus of mice. 38) In contrast, Storozheva et al. 39) found that the administration of MK-801 (50 g/kg) 24 hours after the completion of training in the MWM test improves the resistance of spatial memory to spontaneous extinction. Similarly, treatment with a non-competitive NMDA receptor antagonist such as ketamine or MK-801 can increase neural stem cell proliferation in the hippocampal dentate gyrus. 40, 41) Ketamine in particular alters the proliferation and increases the neuronal differentiation of neural stem progenitor cells in the rat neocortex. 42) Li et al. 43) observed that ketamine increased mTOR signaling activity and increased synaptogenesis and decreased immobility in mice. That is, glutamatergic enhancement may be effect neural plasticity. Although these findings were not confirmed by our results, these differences may be at-tributed to the duration and dosage of NMDA receptor antagonist treatment.
Several studies have demonstrated that SGAs such as olanzapine, clozapine, and quetiapine increase levels of neurogenesis in different regions of the rat brain. [44] [45] [46] [47] More specifically, phencyclidine attenuates neurogenesis in the dentate gyrus of the hippocampus but this can be blocked by clozapine. 35) Similarly, the present results show that olanzapine blocks the attenuation of neurogenesis by MK-801. In previous studies from our lab, olanzapine significantly attenuated serum withdrawal-induced cell loss 48) and increased BDNF gene transcription via an enhancement of CREB-mediated transcription through the PKA, PI3K, PKC, and CaMKII signaling pathways. 49) Moreover, the chronic administration of olanzapine significantly attenuates the decreased expression of these proteins in the rat hippocampus following immobilization stress. 50) Thus, it is proposed here that olanzapine may have has neuroprotective effects and it is likely that this increase in neurogenesis is related to the therapeutic effects of antipsychotic drugs in patients with schizophrenia.
MK-801-induced memory impairment in the MWM test may be improved by treatment with olanzapine, but not haloperidol. In addition, possible olanzapine-induced neurogenesis was observed, suggesting that olanzapine may possess the ability to alter cognitive function in patients with schizophrenia.
